MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

Item

http://www.wikidata.org/entity/Q58164582

description

im Januar 2014 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 23 January 2014

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2014

@uk

name

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

@en

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

@nl

type

Item

label

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

@en

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

@nl

prefLabel

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

@en

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

@nl

P1476

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

@en

P2093

Alberto Rocci

http://www.w3.org/2001/XMLSchema#string

Andrea Bertotti

http://www.w3.org/2001/XMLSchema#string

Anna M Liberati

http://www.w3.org/2001/XMLSchema#string

Antonietta Falcone

http://www.w3.org/2001/XMLSchema#string

Gianluca Isaia

http://www.w3.org/2001/XMLSchema#string

Livio Trusolino

http://www.w3.org/2001/XMLSchema#string

Luca De Rosa

http://www.w3.org/2001/XMLSchema#string

Lucio Catalano

http://www.w3.org/2001/XMLSchema#string

Manuela Gambella

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

P2860

MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis.

Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.

International uniform response criteria for multiple myeloma.

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Drug development of MET inhibitors: targeting oncogene addiction and expedience.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

P304

841-850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12719

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

164

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24450886

http://www.w3.org/2001/XMLSchema#string